Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Tocilizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT02809833

ML22734

Details and patient eligibility

About

This prospective, multicenter, non-interventional study will enroll participants from routine clinical practice in Germany who are receiving tocilizumab for RA. The objective of the study is systematic collection of data on use of tocilizumab in daily routine with special emphasis on treatment decision by the prescriber, compliance with Summary of Product Characteristics (SmPC), and documentation of relevant activity scores and adverse drug reactions (ADRs). The maximum observation period will be 12 months per participant.

Enrollment: 850 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate to severe RA
• Tocilizumab indicated in accordance with SmPC and chosen by the treating physician in advance of the study

Exclusion criteria

• None specified

Trial design

850 participants in 1 patient group

Tocilizumab for RA in Routine Practice

Description:

Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.

Treatment:

Drug: Tocilizumab